Modern biopharma firms are adapting their R&D investment strategies in response to challenges such as the impending $300 ...
Myricx is working on a new "family" of antibody-drug conjugates, which have become an important part of cancer treatment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results